Akebia Expands Renal Disease Portfolio with Cyclerion’s Praliciguat

By Sasha Yachu & Michelle Liu

Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)

Published: 30 Jun-2021

DOI: 10.3833/pdr.v2021.i6.2619     ISSN: 1756-7874

Section: Licensing



Aiming to expand its presence in the renal diseases segment, Akebia Therapeutics has agreed to acquire the global licensing rights to Cyclerion Therapeutics’ praliciguat, an oral soluble guanylate cyclase stimulator...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details